FIRE Funds Income Target ETF FIRI 深 滬
已收盤 10-24 16:00:00 美东时间
18.9449
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 18.9449
- 總市值 123.14万
- 52周最高 19.115
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 17.6612
- 委 比 0.00%
- 總股本 6.50万
- 歷史最高 18.1637
- 量 比 0
- 振 幅 0.00%
- 歷史最低 17.7417
- 每 手 1
- 風險率 0.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FDA Grants Fast Track Designation to Oncolytics Biotech's Pelareorep for KRAS-Mutant MSS Metastatic Colorectal Cancer
FDA Grants Fast Track Designation to Oncolytics Biotech's Pelareorep for KRAS-Mutant MSS Metastatic Colorectal Cancer Oncolytics Biotech Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to pelareorep in combination with bevacizumab (Avastin®) and FOL
02-04 21:50
Cardiff Oncology Reports Positive Phase 2 Results for Onvansertib in First-Line RAS-Mutated mCRC
Cardiff Oncology Reports Positive Phase 2 Results for Onvansertib in First-Line RAS-Mutated mCRC Cardiff Oncology Inc. announced positive interim results from its randomized Phase 2 clinical trial (CRDF-004) evaluating onvansertib in combination with standard of care regimens (FOLFIRI/bevacizumab or
01-28 01:11
BRIEF-Immuneering Announces Positive Data Update From Three Pancreatic Cancer Arms Of Ongoing Phase 2A Trial Of IMM-1-104
Jan 7 (Reuters) - Immuneering Corp IMRX.O: IMMUNEERING ANNOUNCES POSITIVE DATA UPDATE FROM THREE PANCREATIC CANCER ARMS OF ONGOING PHASE 2A TRIAL OF IMM-1-104; PLANS TO EXPAND TRIAL WITH ADDITIONAL AR...
2025-01-07 20:16
